1. Hennino A, Bérard F, Guillot I, et al. Pathophysiology of urticaria. Clin Rev Allergy Immunol 2006; 30: 3-11.
2.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734-66.
3.
Goncu EK, Aktan S, Atakan N, et al. [Turkish guideline for the diagnosis and treatment of urticaria – 2016]. Turkderm Arch Turk Dermatol Venereol 2016; 50: 82-98.
4.
Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers 2022; 8: 61.
5.
Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol 2022; 149: 1137-49.
6.
Metz M, Vadasz Z, Kocatürk E, et al. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol 2020; 59: 38-45.
7.
Acer E, Kaya Erdogan H, Yuksel Canakci N, et al. Comment on “The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticarial”: reply from authors. Cutan Ocul Toxicol 2020; 39: 171.
8.
Asero R, Marzano AV, Ferrucci S, et al. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol 2017; 172: 40-4.
9.
Hon KL, Leung AKC, Ng WGG, et al. Chronic urticaria: an overview of treatment and recent patents. Recent Pat Inflamm Allergy Drug Discov 2019; 13: 27-37.
10.
Onder S, Ozturk M. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria? Cutan Ocul Toxicol 2020; 39: 31-5.
11.
Gokcek GE, Solak EO, Colgecen E. The effect of omalizumab treatment on hematological inflammatory parameters and immunoglobulin E levels in patients with chronic spontaneous urticaria. Turk J Dermatol 2021; 15: 95-101.
12.
Kolkhir P, Altrichter S, Hawro T, et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy 2018; 73: 940-8.
13.
Kolkhir P, André F, Church MK, et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy 2017; 47: 19-36.
14.
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72: 519-33.
15.
Jain S. Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract 2014; 2014: 674709.
16.
Aktas Karabay E, Aksu Cerman A, Kivanc Altunay I. Serum C-reactive protein, neutrophil-lymphocyte ratio and uric acid levels in chronic spontaneous urticaria. Turk Klin J Dermatol 2016; 26: 125-31.
17.
Ozer I. Effects of omalizumab treatment on hematological parameters and total IgE levels in patients with chronic idiopathic urticaria. Mev Med Sci 2021; 1: 37-41.
18.
Ertas R, Ozyurt K, Karakukcu C, et al. Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria. Turk J Med Sci 2018; 48: 1255-62.
19.
Rifaioglu EN, Bulbul Sen B, Ekiz O, et al. Neutrophil to lymphocyte ratio in Behçet’s disease as a marker of disease activity. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 65-7.
20.
Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015; 135: 337-42.e2.
21.
Sarac G, Mantar I, Sener S, et al. Assessment of change in neutrophil-lymphocyte ratio, platelet-lymphocyte ratio in patients with acute and chronic urticaria. Ann Med Res 2018; 25: 719-22.
22.
Obaid JMAS, Almjydy MMA, Garban MAQ, et al. Neutrophil-to-monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity. Health Sci Rep 2023; 6: e1478.
23.
Tamer F. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count. Cutan Ocul Toxicol 2020; 39: 229-32.
24.
Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci 2016; 53: 409-30.
25.
Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148-56.
26.
Kasperska-Zajac A, Grzanka A, Jarzab J, et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int 2014; 2014: 650913.
27.
Chandrashekar L, Rajappa M, Sundar I, et al. Platelet activation in chronic urticaria and its correlation with disease severity. Platelets 2014; 25: 162-5.
28.
Magen E, Mishal J, Zeldin Y, Schlesinger M. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc 2011; 32: 460-6.
29.
Akdogan N, Demirel Ogut N, Gogan S, Atakan N. Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria. Dermatol Ther 2019; 32: e12966.
